Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre Randomized Double-blind Placebo-controlled Study to Evaluate the Effect on Albuminuria of 12 Months Treatment With Hydroxycarbamide (Siklos) or a Placebo in Adults With Sickle Cell Disease

Next Previous
Trial Profile

Multicentre Randomized Double-blind Placebo-controlled Study to Evaluate the Effect on Albuminuria of 12 Months Treatment With Hydroxycarbamide (Siklos) or a Placebo in Adults With Sickle Cell Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxycarbamide (Primary)
  • Indications Sickle cell anaemia
  • Focus Pharmacodynamics
  • Acronyms SIKAMIC
  • Sponsors addmedica

Most Recent Events

  • 27 Aug 2024 Status changed from recruiting to completed.
  • 26 Jan 2023 Planned number of patients changed from 120 to 96.
  • 26 Jan 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top